Navigation Links
CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009

With its Investigational New Drug (IND) application cleared by the U.S. Food and Drug Administration (FDA), Immunovative Therapies, Ltd. (ITL) announced that Phase I/II clinical trials of its experimental CryoStim™ cancer vaccine product for the treatment of advanced metastatic solid tumors will begin September, 2009. CryoStimTM is an individualized cancer vaccine that is made inside the body by combining the experimental AlloStimTM drug with the killing of a selected tumor by the minimally invasive procedure called cryoablation. AlloStimTM contains living immune cells attached to microbeads designed to stimulate and direct the human immune system to directly kill cancer cells wherever they reside in the body. Phase I/II clinical trials will be conducted at its new clinical research subsidiary in Carlsbad, California.

San Diego, California (PRWEB) -- Immunovative Therapies Ltd. ( has announced that its CryoStim™ experimental product has been cleared by the FDA to begin human clinical trials. Immunovative Therapies, Ltd. experimental products are based upon “Mirror Effect™” technology (patents issued and pending) which is designed to provide the same anti-tumor effect that has been proven to be curative in allogeneic bone marrow transplant (BMT) procedures without the lethal toxicity or need for a matched donor.

Immunotherapy is a new modality for cancer treatment which holds great promise for becoming a curative therapy with minimal toxicity. It works together with or replaces current treatment methods. The human immune system is capable of seeking out and destroying cancers cells wherever they reside in the body. Harnessing the power of the immune system holds the greatest potential for winning the battle against cancer.

“CryoStim™ represents a completely novel approach for therapeutic cancer design,” says Michael Har-Noy PhD, CEO and Chief Technical Officer. “Current therapies are not capable of eliminating every last cancer cell in the body and thus tumor recurrence is a common problem. If our experimental therapy is successful it would be possible to not only eliminate every last tumor cells, but also for the immune system to remember the tumor in order to prevent recurrence.”

Details about this cancer vaccine trial can be found at and at NCT00861107. View complete details on products, trial and scientific literature at the company website.

About Immunovative:
Immunovative Therapies, Ltd. (ITL) is an Israeli-based biopharmaceutical company with US facilities in Carlsbad, California. Founded in May 2004 with financial support from Israel’s Office of the Chief Scientist, ITL is a graduate of the Misgav Venture Accelerator, a member of the world renowned Israel technological incubator program. The company was the Misgav Venture Accelerator’s candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate bioengineered living immune cells as the active ingredients for treatment of cancer, autoimmune and infectious disease.

Michael Berger MD at 760-444-9040

In the Pacific Northwest contact Alan F. Hall JD at 425-774-9566


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
Related Image:
CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009
(Date:11/24/2015)... ... November 24, 2015 , ... United ... to welcome Winter-Dent & Company as its newest Partner Firm. Based in Jefferson ... a client's most trusted advisor regardless of whether that client is a business, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for ... with some of the staff members at their recovery center. The videos highlight some ... as some of the things that make their recovery program so unique. , “Making ...
(Date:11/24/2015)... ... 2015 , ... Abington Hospital – Jefferson Health is pleased ... Surgery Facility for treating individuals living with morbid or extreme obesity. , Aetna ... its members to help them make informed decisions about their healthcare needs. In ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty Health Fitness, ... have announced their endorsement of the Medical Fitness Network (MFN), a national health ... have the MFN as one of our endorsed organizations,” said ASH Fitness Vice ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Innovative Blending, a household invention that revolutionizes the vending machine industry by providing ... market is worth $2 billion," says Scott Cooper, CEO and Creative Director of ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 Teledyne DALSA , a ... sensing technology, will introduce its CMOS X-Ray detector for ... November 29 to December 3, at McCormick Place in ... for diagnostic and interventional imaging will be on display in ... of advanced CMOS X-Ray detectors is the industry benchmark ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
(Date:11/24/2015)...   Renowned UAE ... s advice and insights on supplements and healthy diet ... 50% of Dubai residents are not ...   femMED launches comprehensive solutions for women , ... residents are not consuming enough to keep themselves healthy. A local ...
Breaking Medicine Technology: